PDF
(Download)
|
- Green Tea (Camellia sinensis)
- Turmeric (Curcuma longa)
- Curcumin
- Epigallocatechin-3-Gallate
- Non-Hodgkin's Lymphoma
| Date:
06-29-2012 | HC# 021233-451
|
Re: Curcumin and EGCG Induce Remission in B-cell Non-Hodgkin's Lymphoma Patients
Bassiouny
AR, Atteya MA, El-Rashidy FH, Neenaa HM. Curcumin and EGCG suppress apurinic/apyrimidinic
endonuclease 1 and induce complete remission in B-cell non-Hodgkin's lymphoma
patients. Functional Foods in Health and
Disease. 2011;1(12):525-544.
According
to the authors, the incidence of non-Hodgkin's lymphoma (NHL) is increasing,
making it the fifth most common cancer in Egypt. Elevated levels of
apurinic/apyrimidinic endonuclease/redox factor-1 (APE1) in cancers are
indicators of poor prognosis and chemotherapeutic resistance, and the removal
of APE1 sensitizes cancer cell lines to chemotherapeutic agents.1
The efficacy of chemotherapy is increased with the multitargeted regulation of
multiple signaling pathways, including nuclear factor-kappa B (NF-ĸB),
cyclooxygenase-2, apoptosis, and others. These authors hypothesized that
curcumin, a polyphenolic antioxidant derived from turmeric (Curcuma longa), and epigallocatechin-3-gallate
(EGCG) from green tea (Camellia sinensis)
would increase the efficacy of chemotherapy in patients with follicular lymphoma
(FL), a type of NHL. They evaluated the antitumor effect of curcumin and EGCG
in combination with chemotherapy on peripheral blood mononuclear cells in
patients with lymphoma.
Curcumin
and EGCG were selected because they are pharmacologically safe agents that have
been shown to down-regulate NF-ĸB and NF-ĸB-regulated gene products involved in
tumor angiogenesis and metastasis.
The
authors recruited 40 subjects: 10 healthy subjects (control group) and 30 subjects
diagnosed with FL (FL group). The 18 men and 12 women that made up the FL group
were diagnosed with FL at different stages, with histological subtypes.
Blood
samples were drawn from all subjects at baseline, and at 3, 6, 9, and 12
months. Physical activity and the extent of disease were assessed at baseline.
During
the study period, the subjects in the FL group were treated for 9 months with
either the chemotherapy regimen CHOP, CHOP with curcumin, or CHOP with curcumin
and EGCG (CHOP includes cyclophosphamide, hydroxydaunorubicin [also called
doxorubicin or Adriamycin], oncovin [vincristine], and prednisone or
prednisolone). Subjects were followed for 3 months subsequent to the 9-month
treatment.
The
herbal treatment capsules were compatible with curcumin doses between 0.9 and
5.4 g daily (Curcuminoids C3 Complex®; America's Finest, Inc.;
East Windsor, New Jersey) and 9 g of green tea whole extract daily (1,000 mg
tablets of green tea extract containing 200 mg EGCG; Techno-med; Egypt).
CHOP
resistance was defined as occurring in subjects whose disease progressed during
first-line CHOP chemotherapy or who relapsed within 6 months after treatment.
Drug resistance is a major cause of relapse and the incurability of cancer. The
effect of the herbal therapy to overcome the drug resistance of FL subjects to
chemotherapy was estimated by determining glutathione s-transferase (GST)
activities. GST helps defend against free radicals, peroxides, xenobiotics, and
carcinogens.
Attainment
of complete remission was the most important predictor of overall survival; low
serum lactate dehydrogenase (LDH), limited stage disease, and a high serum
albumin were also independently associated with prolonged survival.
The
authors report that adding curcumin and EGCG to the CHOP treatment
significantly lowered cytoplasmic APE1, and the levels of the transcription
factor were lower than those predicted from the effects of the CHOP agents
alone. Eighteen of the subjects had a complete remission, and 12 patients had partial
remission within the 9-month treatment period and the 12-month follow-up
period. They remained disease-free for a mean of 8.6 years (range=7.9-9.2
years) after the combination therapy. According to the authors, this report
provides the first data demonstrating a role of APE1 in lymphoma patients'
survival and function after CHOP treatment.
In
those subjects treated with a combination of CHOP, curcumin, and EGCG, the
serum levels of the angiogenic vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF) were significantly higher than those of
the control subjects before treatment. Significantly reduced serum levels of
both factors were reported in all subjects receiving the combination of CHOP,
curcumin, and EGCG as a first response of the treatment. No P values were
given.
Further
results indicate that adding curcumin to CHOP improved the International Prognostic
Indices (β2 microglobulin and LDH activity) and caused a significant decrease
in both groups of combination therapy after 6 and 9 months of treatment, while
with green tea, the effect was greater than that of curcumin alone. The
chemotherapy-treated group did not show any significant difference in both
factors. The decrease in these parameters was a good prediction for complete
remission rate and a good prognostic effect of both curcumin and green tea, say
the authors.
GST
activity showed a marked increase in the CHOP-only group after 9 months of
treatment and at the 3 month follow-up, while in both combination therapy groups,
GST activity showed a significant decrease. "This gives us an idea about
the ability of both adjuvant therapies (curcumin and EGCG) to overcome the
resistance of NHL patients to chemotherapy," write the authors.
Evaluation
of hepatic and renal function during treatment indicated the absence of any adverse
side effects of the studied adjuvant therapy (curcumin and green tea) in combination
with chemotherapy.
Treatment
of patients' cells with the combination of CHOP, curcumin, and EGCG for 9
months induced significant cell death versus the control, CHOP, or CHOP and
curcumin-treated cells. The number of viable cells reduced significantly
(P<0.05).
The
authors conclude that in the subjects with FL, the combination of curcumin and
EGCG resulted in a synergistic antitumor activity and, with CHOP agents,
down-regulated the expression of all NF-ĸB-regulated gene products, leading to
the suppression of angiogenesis, metastasis, and entering in complete remission
as indicated by β2 microglobulin and LDH levels. The addition of curcumin and
EGCG to CHOP achieved long-lasting remissions in 18 of 30 (60%) subjects with FL.
"These data suggest that the combination of curcumin, EGCG, and CHOP is [a]
highly effective palliative regimen for patients with FL with good performance
status," write the authors.
—Shari
Henson
Reference
1Fishel ML, He Y, Reed
AM, et al. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1
blocks ovarian cancer cell and tumor growth. DNA Repair (Amst). 2008;7(2):177-186
|